Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15331)	2/19/1998 1:54:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Henry, >> Because altered FA {fatty acid } levels are associated with obesity, atherosclerosis, hypertension, & diabetes, PPARs may serve as molecular sensors that are central to the development & treatment of these metabolic disorders.<< For those who thought the LLY deal was principally or only about diabetes, how about these other indications as exciting targets for LLY to deliver blockbuster drugs against by using LGND's PPAR alpha & delta technology? If PPARs are central to their treatment, as the Ronald Evans report indicates, this must be part of the substantial shareholder value buildup that David Robinson felt was going unnoticed by the street. Bernie.